Grant: Idea to Innovation
McGill University
$20,000.00
L2M NSERC - Vascubio: Advancing Perfusion Bioreactor for 3D Bioprinted Vascular Constructs
EF 2023-24
Résumé
A staggering 95% of new drugs fail to reach the market, translating to a significant loss in the $200 billion annual market. The inefficiency and high cost of the drug development process, coupled with the lack of predictability in preclinical screening, contribute to this alarming rate. Pharmaceutical companies invest between $200-500 million USD in preclinical screening per successful drug, highlighting the immense financial burden and risk associated with drug development. There is a need for predictive human mimetic models before clinical trials. VascuBio's bioreactor system provides a faster and more affordable solution to this problem by offering a more accurate and reliable way to test drugs. VascuBio's service offerings include replacement for animal testing in non-essential applications, partnerships with brands like L'oreal for cosmetic testing, and therapeutic development for lung, colorectal, breast, and prostate cancer applications.An innovative bioreactor system designed for 3D bioprinted vascular tissues will be created. This system integrates cutting-edge technology, utilizing medical-grade materials and state-of-the-art monitoring capabilities. With features such as multiplex perfusion, automated rotation, and real-time monitoring. The bioreactor offer predictive human-like models before clinical trials. It is accurate and reliable for drug testing. The multiplex perfusion ensures a thorough simulation of physiological conditions, while automated rotation ensures uniform cell distribution, addressing key issues in experimental flexibility and cell homogeneity.The Total Addressable Market (TAM) for this technology exceeds $200 billion annually, representing the vast landscape of global players seeking advancements in drug development efficiency. Our foundational IP includes a recently filed patent titled "Porous double-network hydrogel" (US20230149307A1). We have published our technology in reputable journals (Adv. Sci., https://doi.org/10.1002/advs.202102627). We plan to strategically file additional patents, safeguarding critical technological features like advanced sensor technology, individual flow control, and automated rotation.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
590843-2024
Name nom
Mongeau, Luc L
Department département
Mechanical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1903
Research subject group en
Biomedical engineering
Research subject group fr
Biomechanics
Research subject en
Génie biomédical
Research subject fr
Biomécanique
Application title
L2M NSERC - Vascubio: Advancing Perfusion Bioreactor for 3D Bioprinted Vascular Constructs
Keyword
Bioprinting; Bioreactors; Mechanical properties; Regenerative medicine; Tissue engineering; Vascular structures
Application summary
A staggering 95% of new drugs fail to reach the market, translating to a significant loss in the $200 billion annual market. The inefficiency and high cost of the drug development process, coupled with the lack of predictability in preclinical screening, contribute to this alarming rate. Pharmaceutical companies invest between $200-500 million USD in preclinical screening per successful drug, highlighting the immense financial burden and risk associated with drug development. There is a need for predictive human mimetic models before clinical trials. VascuBio's bioreactor system provides a faster and more affordable solution to this problem by offering a more accurate and reliable way to test drugs. VascuBio's service offerings include replacement for animal testing in non-essential applications, partnerships with brands like L'oreal for cosmetic testing, and therapeutic development for lung, colorectal, breast, and prostate cancer applications.An innovative bioreactor system designed for 3D bioprinted vascular tissues will be created. This system integrates cutting-edge technology, utilizing medical-grade materials and state-of-the-art monitoring capabilities. With features such as multiplex perfusion, automated rotation, and real-time monitoring. The bioreactor offer predictive human-like models before clinical trials. It is accurate and reliable for drug testing. The multiplex perfusion ensures a thorough simulation of physiological conditions, while automated rotation ensures uniform cell distribution, addressing key issues in experimental flexibility and cell homogeneity.The Total Addressable Market (TAM) for this technology exceeds $200 billion annually, representing the vast landscape of global players seeking advancements in drug development efficiency. Our foundational IP includes a recently filed patent titled "Porous double-network hydrogel" (US20230149307A1). We have published our technology in reputable journals (Adv. Sci., https://doi.org/10.1002/advs.202102627). We plan to strategically file additional patents, safeguarding critical technological features like advanced sensor technology, individual flow control, and automated rotation.